How to read: Every bubble is one Indian cisplatin exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Cisplatin report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial cisplatin trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian cisplatin suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Cisplatin India trade report
P
Product scope
Cisplatin
All variants merged — branded and generic formulations of cisplatin
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
144
Every commercial cisplatin trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a mixed: Oct $21.6K, Nov $454.6K, Dec $174.7K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$21.6K
Oct USD
7 shipments
2
$454.6K
Nov USD
+2004.8% MoM
3
$174.7K
Dec USD
-61.6% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 2004.8% in USD but shipment count kept climbing.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $22K, making it the weakest month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: VENUS REMEDIES LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import cisplatin from India, how much they buy, and who supplies each market
KEY TAKEAWAYTaiwan absorbs 36.1% of India’s 2025-Q4 cisplatin trade ($235.2K). Beyond the top 10 destinations, 51 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 20 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 51 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much cisplatin India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$393K
60.3% of trade
20 countries · 51 shipments
Europe
$34K
5.3% of trade
5 countries · 10 shipments
Americas
$141K
21.6% of trade
8 countries · 19 shipments
Africa
$82K
12.6% of trade
18 countries · 62 shipments
Oceania
$975
0.1% of trade
1 countries · 2 shipments
Fig 4.1 Taiwan is the #1 corridor ($235K) — 30 flow arcs from India radiate across 5 continents.
How to read: The world map shows every country colored by how much Indian cisplatin it receives (light = low, dark = high). Orange arcs radiate from India to the top 30 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
Taiwan
$235K
2
FRESENIUS KABI ONCOLOGY LTD
$235K
—
—
—
—
2
Sri Lanka
$95K
10
KHANDELWAL LABORATORIES PVT LTD
$95K
VAMA LIFECARE PVT LTD
$1
—
—
3
Mexico
$46K
11
VENUS REMEDIES LTD
$42K
MYGENIC HEALTHCARE PVT LTD
$3K
MEDINEX HEALTHCARE
$857
4
Colombia
$37K
1
VENUS REMEDIES LTD
$37K
—
—
—
—
5
Ethiopia
$37K
11
BETA DRUGS LTD
$37K
MATOSHREE HEALTH CARE PVT LTD
$443
—
—
6
Chile
$29K
1
FRESENIUS KABI ONCOLOGY LTD
$29K
—
—
—
—
7
Ecuador
$26K
2
FRESENIUS KABI ONCOLOGY LTD
$26K
—
—
—
—
8
Kenya
$21K
15
GETWELL PHARMA INDIA PVT LTD
$9K
R.S. SURGIPHARM PVT LTD
$6K
UNITED BIOTECH PVT LTD
$4K
9
Lithuania
$18K
2
UNITED BIOTECH PVT LTD
$18K
SPECIALITY MEDICINES LTD
$364
—
—
10
China
$17K
4
KAYGEE IMPEX
$9K
FAMN PHARMA PVT LTD
$7K
JMB PHARMACEUTICALS PVT LTD
$2K
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 60.3% of USD — but Taiwan is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
36.1%
#1 country share
Taiwan alone
69.2%
Top 5 share
5 of 52 countries
93.9%
Top 15 share
Long tail of 37 countries = 6.1%
HHI 1710
Destination HHI
Moderately concentrated
52
Countries served
Global pharma reach from India
20
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
58 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYFRESENIUS KABI ONCOLOGY LTD ($290.1K, 44.6% share) and KHANDELWAL LABORATORIES PVT LTD ($100.0K) together control 59.9% of India’s 2025-Q4 cisplatin trade. The top 5 suppliers hold 83.3%. 58 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian cisplatin suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 FRESENIUS KABI ONCOLOGY LTD leads by $190K over KHANDELWAL LABORATORIES PVT LTD — top 20 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: MYGENIC HEALTHCARE PVT is #16 by value but #6 by volume.
Fig 5.2 KHANDELWAL LABORATORIES PVT LTD also leads by shipment count (11) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: MYGENIC HEALTHCARE PVT moves from #6 by volume to #16 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 58 cisplatin suppliers split into strategic segments
KEY TAKEAWAY15 suppliers (25%) generate 95.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 FRESENIUS KABI ONCOLOGY LTD and KHANDELWAL LABORATORIES PVT LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 95.6% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 1 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 1 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 1 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
54 importers across 52 countries — who is buying Indian cisplatin and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 25 importers together hold only 85.8% of total USD. 96% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian cisplatin. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 FRESENIUS KABI TAIWAN LTD is the #1 importer at $235K (36.1%) — top 25 by trade value
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian cisplatin prices vary by supplier, country and dosage form
KEY TAKEAWAYCisplatin prices span 494× ($0.020 → $9.90). The coefficient of variation is 0.73. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. KHANDELWAL LABORATORIES PVTSourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. FRESENIUS KABI ONCOLOGYSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. KAYGEE IMPEXSourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. DOSSMEGT PHARMACEUTICALS PVTSourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Nov 2025
CHAWLA MEDICOS
Ghana
Injection
170
$2K
$9.90
Sterile formulation premium
Nov 2025
CHAWLA MEDICOS
Ghana
Injection
30
$296.93
$9.90
Sterile formulation premium
Nov 2025
GETWELL PHARMA I…
Kenya
Injection
900
$9K
$9.66
Sterile formulation premium
Dec 2025
MENAMED PHARMA P…
Burkina Faso
Injection
100
$846.39
$8.46
Sterile formulation premium
Nov 2025
ARYSON HEALTHCAR…
Laos
Injection
320
$2K
$7.73
Sterile formulation premium
Nov 2025
ARYSON HEALTHCAR…
Laos
Injection
80
$610.82
$7.64
Sterile formulation premium
Nov 2025
DOSSMEGT PHARMAC…
Haiti
Tablet
300
$2K
$5.96
Specialty / small-batch
Nov 2025
FRESENIUS KABI O…
Ecuador
Injection
2K
$14K
$5.78
Sterile formulation premium
Nov 2025
SHARVIK IMPEX (I…
Jamaica
Tablet
40
$229.74
$5.74
Specialty / small-batch
Nov 2025
SANSKRUTI PHARMA
Burkina Faso
Injection
75
$430.49
$5.74
Sterile formulation premium
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Dec 2025
ADMAC LIFESCIENCES
Myanmar
Injection
2K
$15.21
$0.010
Sterile formulation premium
Dec 2025
VHB MEDI SCIENCE…
Namibia
Injection
2K
$36.70
$0.020
Sterile formulation premium
Dec 2025
RMPL PHARMA LLP
Turkey
Vial
300
$6.95
$0.023
Small sample / trial shipment
Dec 2025
BETA DRUGS LTD
Ethiopia
Injection
561
$13.42
$0.024
Sterile formulation premium
Dec 2025
BETA DRUGS LTD
Ethiopia
Injection
6K
$142.81
$0.024
Sterile formulation premium
Dec 2025
BETA DRUGS LTD
Ethiopia
Injection
939
$22.46
$0.024
Sterile formulation premium
Dec 2025
BETA DRUGS LTD
Ethiopia
Injection
6K
$143.01
$0.024
Sterile formulation premium
Dec 2025
BETA DRUGS LTD
Ethiopia
Injection
5K
$119.35
$0.024
Sterile formulation premium
Dec 2025
ONCOHEAL HEALTHC…
Laos
Injection
50
$1.39
$0.028
Sterile formulation premium
Dec 2025
VAMA LIFECARE PV…
Sri Lanka
Injection
50
$1.44
$0.029
Sterile formulation premium
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship cisplatin, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYCisplatin leaves India through 7+ ports. The top 5 (DELHI AIR, MUMBAI AIR (SAHAR), AHMEDABAD AIR) handle 99.1% of total USD. AIR moves 94% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 DELHI AIR handles $464K — top 7 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYAIR dominates at 94% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$622K
95.6% of USD · 94.4% of ships
ICD
$23K
3.5% of USD · 2.8% of ships
SEA
$6K
0.9% of USD · 2.8% of ships
Fig 8.3 The dominant corridor is DELHI AIR → Air → Asia ($256K).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYSri Lanka is the most concentrated destination (HHI 10000, 2 suppliers). Kenya is the most competitive (HHI 2986).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Sri Lanka (HHI 10,000) is the most concentrated — Kenya (HHI 2,986) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
FRESENIUS KABI TAIWA…
Taiwan
FRESENIUS KABI O…
$235K
2
HIGH
PEOPLES BANK
Sri Lanka
KHANDELWAL LABOR…
$95K
9
MEDIUM
U T S D C
Mexico
VENUS REMEDIES LTD
$42K
2
MEDIUM
A.SAS
Colombia
VENUS REMEDIES LTD
$37K
1
MEDIUM
FRESENIUS KABI CHILE…
Chile
FRESENIUS KABI O…
$29K
1
MEDIUM
FRESENIUS KABI S.A
Ecuador
FRESENIUS KABI O…
$26K
2
MEDIUM
SEASONS PHARMACEUTIC…
Zimbabwe
NAPROD LIFE SCIE…
$11K
2
MEDIUM
GALINOS FARM DOO ILI…
North Macedonia
OCEAN PHARMACEUT…
$10K
3
MEDIUM
Conclusion: 52 buyers depend on exactly one Indian supplier, representing $566K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
Taiwan
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Sri Lanka
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Mexico
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Colombia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Ethiopia
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Chile
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Ecuador
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Kenya
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Lithuania
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
China
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Cambodia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Zimbabwe
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Philippines
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
North Macedonia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Slovakia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 14 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in Taiwan
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Sri Lanka lock-ins (HHI 10000)
This Q
MED
A5
Enter Taiwan (1 suppliers)
This Q
HIGH
A6
Enter Sri Lanka (2 suppliers)
This Q
MED
A8
Build Sri Lanka distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for Taiwan tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
Taiwan
Asia
1
$235K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
2
Sri Lanka
Asia
2
$95K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
3
Mexico
Other
4
$46K
0%
LOW
Low competition (4 suppliers), accessible market
4
Colombia
Other
1
$37K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
5
Ethiopia
Africa
2
$37K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
6
Chile
Other
1
$29K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
7
Ecuador
Other
1
$26K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
8
Lithuania
Other
2
$18K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
9
DR Congo
Africa
2
$174
+9873.6%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
10
China
Asia
3
$17K
-100%
LOW
Low competition (3 suppliers), accessible market
11
Cambodia
Asia
3
$12K
-95.1%
LOW
Low competition (3 suppliers), accessible market
12
Zimbabwe
Africa
1
$11K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
13
Philippines
Asia
2
$10K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
14
North Macedonia
Other
1
$10K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
Slovakia
Other
1
$6K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
This report covers 144 2025-Q4 Cisplatin shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/cisplatin
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 144 2025-Q4 cisplatin shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian cisplatin shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
144
across all regions
TOTAL USD
$651K
2025-Q4 FOB value
UNITS
245.6K
tablets, capsules, etc.
SUPPLIERS
58
Indian exporters
BUYERS
54
global importers
COUNTRIES
52
destinations
§10.2 Regional breakdown
Africa
$82K
12.6%
18 ctry · 62 ships
Asia
$393K
60.3%
20 ctry · 51 ships
Europe
$34K
5.3%
5 ctry · 10 ships
Americas
$141K
21.6%
8 ctry · 19 ships
Oceania
$975.25
0.1%
1 ctry · 2 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $82K (12.6%), spanning 18 countries.
🏢
58 Indian suppliers shipped to 54 buyers across 52 countries — average shipment value $5K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 52 global cisplatin importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian cisplatin in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
FRESENIUS KABI TAIWAN LTD
Taiwan
2
$235K
FRESENIUS KABI ONCOL…
Injection
2
PEOPLES BANK
Sri Lanka
9
$95K
KHANDELWAL LABORATOR…
Injection
3
U T S D C
Mexico
2
$42K
VENUS REMEDIES LTD
injectable solution
4
A.SAS
Colombia
1
$37K
VENUS REMEDIES LTD
Injection
5
FRESENIUS KABI CHILE LTDA
Chile
1
$29K
FRESENIUS KABI ONCOL…
Injection
6
FRESENIUS KABI S.A
Ecuador
2
$26K
FRESENIUS KABI ONCOL…
Injection
7
SEASONS PHARMACEUTICALS PVT LTD
Zimbabwe
2
$11K
NAPROD LIFE SCIENCES…
Injection
8
GALINOS FARM DOO ILINDEN
North Macedonia
3
$10K
OCEAN PHARMACEUTICAL
Injection
9
NAIROBI ENTERPRISES LTD
Kenya
2
$9K
GETWELL PHARMA INDIA…
Injection
10
LIAONING SA
China
1
$9K
KAYGEE IMPEX
Injection
11
SAK CAM PHARMA CO LTD
Cambodia
1
$7K
UNITED BIOTECH PVT LTD
Injection
12
AGB PHARMACEUTICAL TRADING
Philippines
2
$7K
GETWELL PHARMA INDIA…
Solution
13
DALIAN FAIRUS TRADING CO LTD
China
2
$7K
FAMN PHARMA PVT LTD
Injection
14
AL-NOOR FOR DRUGS & MEDICAL APPLIAN
Yemen
4
$6K
J.A. UNITED EXPORTS …
Injection
15
N L N
Myanmar
1
$5K
VENUS REMEDIES LTD
Injection
16
FAIR DEAL CAMBODIA LTD
Cambodia
1
$4K
VHB MEDI SCIENCES LTD
Injection
17
SALAMA PHARMACEUTICALS LTD
Kenya
2
$4K
UNITED BIOTECH PVT LTD
Injection
18
MEDETHIX INC
Philippines
1
$4K
KHANDELWAL LABORATOR…
Solution
19
IC PHARMA LAO CO LTD
Laos
2
$3K
ARYSON HEALTHCARE PV…
Injection
20
VISION CARE INTERNATIONAL PVT LTD
Nepal
1
$2K
GETWELL PHARMA INDIA…
Injection
21
HOPITAL CARAMED CLINIQUE DU CANCE
Haiti
1
$2K
DOSSMEGT PHARMACEUTI…
Tablet
22
DALIAN CHAOHONGSUPPLY CHAIN MANAGEM
China
1
$2K
JMB PHARMACEUTICALS …
Injection
23
LOTUS PHARMA
Burundi
1
$2K
KHANDELWAL LABORATOR…
Injection
24
LLC TIBBI JAHON
Tajikistan
2
$1K
M.K.PHARMA
Vial
25
ETEMED MOSLEH LTD
Afghanistan
1
$1K
RESCUERS LIFE SCIENC…
Solution
26
EHSAN COMERCIO GERAL LDA
Angola
1
$1K
HAMD OVERSEAS
Injection
27
NIKHIL PHARMA PVT LTD
Nepal
2
$863.77
UNITED BIOTECH PVT LTD
Injection
28
GOLD TREE PHARMACEUTICALS LTD
Kenya
1
$837.21
ASPIDA LIFE SCIENCES…
Injection
29
CENTRALE D ACHATS DE MEDICAMENTS
Madagascar
1
$821.43
ZUVIUS LIFESCIENCES …
Injection
30
CENTRAIMED
Equatorial Guinea
2
$504.70
PIRZE LIFECARE PVT LTD
31
ABU AHMED
Kenya
1
$497.05
AMARI TRADE ALLIANCE…
Injection
32
FOR THE ORDER OF
Kenya
2
$479.37
3S CORP
Injection
33
M O H P H
Bahamas
1
$449.62
VENUS REMEDIES LTD
Injection
34
SALAMA NIGERIA LTD
Benin
1
$318.10
ZAHIDI ENTERPRISE
Injection
35
ATLAS TRADING COMPANY
Iraq
1
$313.22
VATS INDUSTRIES PVT …
Injection
36
COSPHARM INVESTMENT
Namibia
2
$277.12
VHB MEDI SCIENCES LTD
Injection
37
JOAN DAVIS
Jamaica
1
$229.74
SHARVIK IMPEX (INDIA…
Tablet
38
CENTRALE DACHATS DE MEDICAMENTS
Madagascar
2
$214.68
GETWELL PHARMA INDIA…
Injection
39
ZMC EXPRESS CARGO FZCO
United Arab Emirates
1
$154.05
SEATRACK INTERNATION…
Injection
40
STATE TRADING ORGANIZATION PLC
Maldives
3
$117.40
MC PHARMA DISTRIBUTORS
Injection
41
GRAND PRECISION PHARMACEUTICALS CO
Myanmar
2
$114.86
ADMAC LIFESCIENCES
Injection
42
TAIWO ADEYEMI
Nigeria
1
$83.67
V S INTERNATIONAL PV…
Injection
43
B P & G S W
Bahrain
1
$37.31
VENUS REMEDIES LTD
Injection
44
MENNA PHARMACEUTICALS IMPORT PLC
Ethiopia
4
$35.88
BETA DRUGS LTD
Injection
45
CANCER INSTITUTE OF LIBREVILLE
Gabon
1
$16.91
ALDE MEDI IMPEX LTD
Injection
46
ABU ABDU
Turkey
1
$12.66
AMARI TRADE ALLIANCE…
Injection
47
AS PER INVOICE GHANA
Ghana
1
$10.00
VAMA HEALTH WORLD LLP
Injection
48
AS PER INVOICE MEXICO
Mexico
1
$8.16
VAMA HEALTH WORLD LLP
Injection
49
QUALIMETRIX SA
Greece
1
$1.74
VENUS REMEDIES LTD
concentrate
50
AS PER INVOICE SRI LANKA
Sri Lanka
1
$1.44
VAMA LIFECARE PVT LTD
Injection
51
SUNCREST INTERNATIONAL LTD
Trinidad and Tobago
1
$0.998
GETWELL PHARMA INDIA…
Injection
52
STATE INSTITUTION PROCUREMENT
Uzbekistan
1
$0.0000
RR PHARMACEUTICALS P…
solution for infusion
This report covers 144 2025-Q4 Cisplatin shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/cisplatin
Talk to our trade analyst
Need a custom cisplatin report or a deeper dive into any market? Our team is ready.